Connect with us

June Monthly

The US dollar, which confounded most observers by appreciating in the first quarter, has fallen broadly in April and May.  The drivers, ironically, are the same:  US rates and relative economic strength.  Treasury yields rose sharply in Q1, and this…

Published

on

The US dollar, which confounded most observers by appreciating in the first quarter, has fallen broadly in April and May.  The drivers, ironically, are the same:  US rates and relative economic strength.  Treasury yields rose sharply in Q1, and this helped the greenback recover from the accelerated slide in November and December 2020. However, they fell in April and did not get much traction in May.  Spikes higher in yields, such as in response to the surprising acceleration of CPI to over 6% at an annualized rate in the first four months of the year, were short-lived.  

Federal Reserve officials say it is too early to consider tapering, and even the few that have suggested more willingness to discuss it, require a few more months of data. That means outside updated forecasts, no change in its stance should be expected from the June 15-16 FOMC meeting.  A Bloomberg survey found a majority expect tapering to begin in Q4. The December 2022 Eurodollar futures contract has a 25 bp rate hike discounted more than a year before the majority of the Fed (11/18) thinks it will be appropriate.  

US economic data has not surprised to the upside as it did earlier in the year. Instead, three significant disappointments, non-farm payrolls, retail sales, and housing starts, marred April's reports and forced many economic models to temper projections of Q2 GDP.  That said, the economy still appears to be accelerating after growing at a 6.4% annualized clip in Q1.  Yet, at the same time, the pace of activity will likely peak in the middle two quarters of the year as the sugar-rush of fiscal spending begins to fade, and the surge associated with the re-opening fades.  

Meanwhile, the vaccine rollout in Europe has taken off, and economic activity is recovering quickly.  Since mid-March, the ECB had stepped up its bond purchases, and there will be a vigorous debate at the June 10 meeting whether some reduction is in order.  The rise in yields in recent weeks appears to have been driven by domestic rather than global considerations.  Still, if the bond-buying pace slows, it may not be fair to call this tapering.  It is more like what the Bank of Canada did last year, and the Bank of Japan and the Reserve Bank of New Zealand have done. For different reasons, there was a recalibration of the long-term asset purchases without the intent of reducing the stimulus.  

The European Union's fiscal initiative and budget have still not been ratified by all the members.  Nor have all the spending plans been submitted.  The recovery fund may not be up and running until well into Q3, and when it does disburse funds, it will be pro-cyclical in the sense of helping economies that are already rebounding. The UK contracted in January and February, but as the vaccine rollout improved, economic growth accelerated.  Despite the Indian mutation of the pathogen, the UK is still on track from an economy-wide re-opening on June 21.  The Bank of England reduced its weekly bond purchases intending to complete them by the end of the year.  

Japan is having a more challenging time of things. It is one of the few countries that is experiencing deflation (negative year-over-year CPI).  Although the infliction numbers remain relatively modest, the formal state of emergency covering an area accounting for around 40% of GDP has been extended into June.  A proper recovery may begin in Q3, but it may not be in enough time to help Prime Minister Suga, who faces a party leadership contest in September, and his decision to go forward with the Olympics (opening ceremonies July 23) is terribly unpopular.  A decision is expected in June whether local spectators will be allowed to attend in person.  The number of foreign attendees was cust in March from 600,000 to less than 70k.

Tax reform and coordination have been stymied at the OECD in recent years, largely but not solely because of the US intransigence.  The US proposal for a 15% minimum corporate tax rate could be the basis of an agreement, and the first step is to reach a G7 consensus.  Separately is the issue of the digital tax, which the US objects to because it singles out US companies.  Some level of taxation for where sales are made applied to the largest companies seems to offer the possible basis of a compromise.  Successful endorsement by the G7 finance ministers (June 4-5) and the heads of state summit (June 11-13) will also help US President Biden's domestic agenda.  He seeks to unwind the 2017 corporate tax cut and lift the rate back to 28% from 21%, with many exemptions and breaks. The average effective corporate tax rate is seen several percentage points lower (Yardeni estimates 2020 effective corporate tax rates were slightly below 16%). 

A straightforward way to frame the developments among the major currencies is to consider that the dollar is at the fulcrum of a seesaw.  The currencies that have appreciated against the dollar are those from countries that the central bank has adjusted monetary policy or forward guidance suggesting a less accommodative stance:  Canada, UK, Norway, and New Zealand.  Those laggards, led by Japan (yen is off 6% through May), have weaker currencies.  The Australian dollar is posting a negligible gain and is the exception to the pattern.  

China demonstrated that it is a force to reckon with. Officials reiterated its 2019 ban on banks and payment companies transacting in crypto and underscored that the prohibitions included mining (creating tokens by solving highly rarified math problems).  While some other countries are banning crypto, the G7 seems more likely to regulate it, tax it, ensure that it is not being used to conceal payments for criminal activity. 

More importantly, China officials sought to limit the increase in commodity prices.  It appears to be doing this through its regulatory authority. One illustrative example is the local government of Tangshan, the main steel-making city.  According to reports on Reuters and Bloomberg, it warned that it would look into illegal behavior and suspend production from mills found to be manipulating prices by spreading rumors or hoarding materials.  The local government also introduced output curbs on steel as part of the crackdown on pollution.  The central government has also been explicit with similar threats.  And it appeared to have the desired effects of commodity prices, where various industrial commodities snapped multi-week advances. 

The JP Morgan Emerging Market Currency Index rose for the second consecutive month after falling every month in Q1.  However, there was a significant variance in performance.  Eastern and Central Europe dominated the advancers, with Russia counting for five of the top ten.  The Hungarian forint was the strongest in the region last month, rising almost 5% against the dollar and 3.50% against the euro.  Among emerging market currencies, Asian currencies underperformed.  The Indian rupee was a notable exception. It rose by about 2.25%.  Latam currencies were mixed.  The Brazilian real and Mexican peso gained about 4% and 1.6%, respectively, against the dollar.  Political jitters dragged the Chilean peso down by around 1.8%, making it the weakest.  The Colombian peso proved fairly resilient to S&P's decision to take away its investment-grade status and rose by about 0.6% in May.  

Bannockburn's World Currency Index, a GDP-weighted basket of the 10-largest economies, made new three-year highs in May as it continued to recover.  The pullback in Q1 (dollar bounce) seems more clearly a counter-trend correction.  The US dollar fell against all the currencies in the index, but the South Korean won.  The won was among the weakest currencies in May, falling 1.3%.  Weaker tech shares and re-allocation by foreign investors (~$8.6 bln in May after buying ~$245 mln in April).  The related outflow was blunted by foreign purchases of $5.6 bln of Korean bonds. Foreign investors bought almost $30 bln of bonds in Q1.  

It is often difficult to divine the intent and meaning of the People's Bank of China.  Our working hypothesis is that officials allow it to move in line with the other major currencies within certain bounds. For example, the euro and the yuan both comprise about a fifth of the Bannockburn World Currency Index.  On a 60-day rolling basis, the correlation of the percent change of the yuan and euro is at a three-year high of nearly 0.58.  Some observers argue that the causal arrow begins with China, but we are less sanguine.  The PBOC seems largely reactive, including in the setting of the daily reference rate, which had become more transparent.   


Dollar:  Given the large fiscal shortfall and the record trade deficit, US interest rates need to rise in absolute terms and relative to other major countries, or the dollar bears the burden of adjustment.  The Federal Reserve has made it clear it is not ready to take its foot off the monetary accelerator and will continue to buy $120 bln a month of Treasuries and mortgage-backed securities.  It is unlikely to change its stance at the mid-June FOMC meeting, but the market will emphasize the possible fraying of the consensus that a rate hike will not be appropriate until after 2023.   Last December, five disagreed (of 17), and in March, seven (of 18) thought that a move earlier would be needed.  Disappointing April jobs growth and weakness in consumption speak to the uneven recovery underway.   The implied yield of the December 2022 Eurodollar futures contract stands near 38 bp, down from 50 bp at the end of March and about 44 bp at the end of April.  The base effect on inflation should diminish until later in the year. However, the bottlenecks and supply chain disruptions still may be evident, lifting prices and dampening activity, such as auto output.

 

Euro:  In contrast to the US, European data has generally surprised on the upside as the vaccination efforts intensified and some social restrictions eased. By the end of July, the EU will have enough vaccines to inoculate 70% of its adult population. Economic growth is accelerating after the Q1 contraction. There is arguably too much attention being devoted to the debate at the ECB about reducing the bond purchases under the Pandemic Emergency Purchase Program after increasing it in March.  Since the March ECB meeting, the euro appreciated by about 2.5% after falling almost the same magnitude from the end of 2020 until that March decision.  Arguably, more importantly, the US premium over Germany for both two and ten-year borrowings narrowed after rising in Q1.  Geopolitical tensions with Russia and Belarus have had little market impact.  The EU continues to resist UK efforts to revise the Withdrawal Agreement and the Northern Ireland protocol.  Until Beijing's retaliatory sanctions are lifted, the EU Parliament will not ratify the Comprehensive Agreement on Investment deal struck with China at the end of last year.  

 

(May 28 indicative closing prices, previous in parentheses)

 

Spot: $1.2190 ($1.2020)

Median Bloomberg One-month Forecast $1.2100 ($1.2010) 

One-month forward  $1.2200 ($1.2025)    One-month implied vol  5.7%  (5.3%)    

 

 

Japanese Yen:  The link between the US 10-year yield and the dollar-yen exchange rate had slacked last year, but it has returned to near pre-crisis levels (~0.65 60-day correlation on changes in two instruments).  On the other hand, the correlation between the exchange rate and the S&P 500 (proxy for risk) has become inverted (yen strengthens when stocks rise), which rarely happens, and by the most since 2012. The slowness to roll out the vaccine in Japan, the extended emergencies, negative terms of trade shock (i.e., rising commodity prices), and the return of deflation provide a weak backdrop for the yen.  A poor Olympics may be more of a drag on Prime Minister Suga's chances of remaining LDP leader and therefore Prime Minister than having canceled them.  Higher US rates can lift the dollar toward this year and last year's highs in the JPY111.00-JPY112.25 area.  

 

Spot: JPY109.85 (JPY109.30)      

Median Bloomberg One-month Forecast JPY109.00 (JPY108.60)     

One-month forward JPY110.00 (JPY109.00)    One-month implied vol  5.5% (5.5%)  

 

 

British Pound:  Sterling led the major currencies higher against the dollar, rising 2.5% in May.  It was the fourth month this year it has appreciated against the dollar and the sixth in the past seven months.  This still does not do justice to sterling's advance. The pound typically falls in May.  Last month was the first time it appreciated in 12 years.  The economy is accelating. The Bank of England slowed its bond purchases and intends on completing them before the end of the year.  Plans to re-open the economy fully on June 21 are being challenged by the rising infections and hospitalizations as May drew to a close.  Until the course of the virus and the impact of the end of the furlough job-subsidy initiative, expectations for a policy change will be restrained.  A rate hike in late 2022 appears to be discounted in the futures market.  The UK holds the presidency of the G7, and a successful summit that will be held in picturesque Carbis Bay would be a good way to launch post-Brexit UK diplomatic leadership.   

  

Spot: $1.4190 ($1.3820)   

Median Bloomberg One-month Forecast $1.4000 ($1.3860) 

One-month forward $1.4200 ($1.3825)   One-month implied vol 6.7% (6.9%)

  

 

Canadian Dollar:  The Bank of Canada's decision to reduce its bond-buying and bring forward when the output gap would be closed (to H2 22) on April 21 sparked about a 4.5% rally in the Canadian dollar.  The US dollar found support just above CAD1.20, an important technical area.  Although the greenback's downside momentum stalled, it continues to struggle to sustain upticks. Still, the risk is that the market has gotten a bit ahead of itself.  Speculators in the futures market have the largest gross long Canadian dollar position in four years.  The market has nearly three rate hikes discounted by the middle of 2023.  Another weak job report (unexpected loss of almost 130k full-time positions in April) could prompt the Bank of Canada to soften its rhetoric at the June 9 meeting. In the middle of May, Prime Minister Trudeau announced an extension of the border restrictions with the US until June 21.  Polls suggest there is not much public pressure to lift it until at least after the summer.    

 

Spot: CAD1.2075 (CAD 1.2290) 

Median Bloomberg One-month Forecast  CAD1.2300 (CAD1.2400)

One-month forward CAD1.2080 (CAD1.2300)    One-month implied vol  6.6%  (6.2%) 

 

 

Australian Dollar: Contrary to conventional wisdom, the Australian dollar is not a proxy for commodities. The Australian dollar peaked in late February, a little above $0.8000.  While commodity prices have risen until recently, the Aussie has moved broadly sideways between around $0.7675 and $0.7855.  Through the first five months of the year, the Australian dollar is up an inconsequential 0.25%.  Capital flows are more important than trade flows, and the usual premium Australia typically offers over the US to borrow for two years remains at a discount.  Although the Reserve Bank of New Zealand signaled that it could raise rates in H2 22, the Reserve Bank of Australia is in no hurry to follow suit.  The June 1 meeting is less important than the July 6 meeting at which the RBA will announce whether it will extend its bond-buying program (which currently expires at the end of September) and whether it will continue to its yield curve control efforts.   

 

Spot:  $0.7710 ($0.7715)       

Median Bloomberg One-Month Forecast $0.7750 ($0.7705)     

One-month forward  $0.7715 ($0.7720)     One-month implied vol 8.5  (8.6%)   

 

 

Mexican Peso:  The peso gained almost 1.7% against the dollar in May, twice April's gain, and it is now flat on the year.  The JP Morgan Emerging Market Currency Index is also virtually unchanged through the first five months of the year.  The growth prospects have improved, helped by the strength of the US economy.  Worker remittances remain strong.  Price pressures have accelerated, and the central bank recognizes upside risks. Although Banxico seems to be in no hurry to signal a hike, the market appears to be pricing in nearly 100 bp of hikes over the next year.   Brazil has hiked the Selic rate twice by 75 bp each time and has signaled it will do so again at the June 16 meeting.  This will take it to 4.25% compared with Mexico's 4.00% target.  At the beginning of the year, the Selic was at half of Mexico's 4% cash target. From a particularly violent campaign season, Mexico holds legislative and local elections on June 6. President AMLO's party (Morena, or National Regeneration Movement) is expected to do well

 

Spot: MXN19.9380 (MXN20.2460)  

Median Bloomberg One-Month Forecast  MXN20.2250 (MXN20.3820)  

One-month forward  MXN20.01 (MXN20.3150)     One-month implied vol 11.6% (12.5%)

  

 

Chinese Yuan:  Beijing took action to curb the rise in commodities and reaffirmed its ban on the crypto ecosystem, but it seemed to do little to check the yuan's steady advance in May to new three-year lows.  It only fell in four sessions last month.  However, at the end of the month, the PBOC raised the reserve requirement for foreign exchange by two percentage points to 7%, which may temper the enthusiasm. If the persistence was notable, the pace was not.  The yuan rose about 1.4% against the dollar.  PBOC officials say that they monitor the currency against a basket of 24 trading partners and the yuan rose to five-year highs against it.  Inflows into China's bonds and stocks were reported after they had appeared to have slowed.  Talk that officials would embrace currency appreciation to offset the rise in commodity prices was explicitly rejected by the PBOC.  That said, given that the yuan is closely managed, the fact that it has appreciated would seem to reflect the fact that key officials judge that the costs of a modest rise in the yuan (~2.25% year-to-date) are worth the price of resisting.

 

Spot: CNY6.3685 (CNY6.4750)

Median Bloomberg One-month Forecast  CNY6.4650 (CNY6.4885) 

One-month forward CNY6.3760 (CNY6.4900)    One-month implied vol  5.0% (4.7%)



Disclaimer


Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Government

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19…

Published

on

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19 vaccination was a mistake due to ethical and other concerns, a top government doctor warned Dr. Anthony Fauci after Dr. Fauci promoted mass vaccination.

Coercing or forcing people to take a vaccine can have negative consequences from a biological, sociological, psychological, economical, and ethical standpoint and is not worth the cost even if the vaccine is 100% safe,” Dr. Matthew Memoli, director of the Laboratory of Infectious Diseases clinical studies unit at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), told Dr. Fauci in an email.

“A more prudent approach that considers these issues would be to focus our efforts on those at high risk of severe disease and death, such as the elderly and obese, and do not push vaccination on the young and healthy any further.”

Dr. Anthony Fauci, ex-director of the National Institute of Allergy and Infectious Diseases (NIAID. in Washington on Jan. 8, 2024. (Madalina Vasiliu/The Epoch Times)

Employing that strategy would help prevent loss of public trust and political capital, Dr. Memoli said.

The email was sent on July 30, 2021, after Dr. Fauci, director of the NIAID, claimed that communities would be safer if more people received one of the COVID-19 vaccines and that mass vaccination would lead to the end of the COVID-19 pandemic.

“We’re on a really good track now to really crush this outbreak, and the more people we get vaccinated, the more assuredness that we’re going to have that we’re going to be able to do that,” Dr. Fauci said on CNN the month prior.

Dr. Memoli, who has studied influenza vaccination for years, disagreed, telling Dr. Fauci that research in the field has indicated yearly shots sometimes drive the evolution of influenza.

Vaccinating people who have not been infected with COVID-19, he said, could potentially impact the evolution of the virus that causes COVID-19 in unexpected ways.

“At best what we are doing with mandated mass vaccination does nothing and the variants emerge evading immunity anyway as they would have without the vaccine,” Dr. Memoli wrote. “At worst it drives evolution of the virus in a way that is different from nature and possibly detrimental, prolonging the pandemic or causing more morbidity and mortality than it should.”

The vaccination strategy was flawed because it relied on a single antigen, introducing immunity that only lasted for a certain period of time, Dr. Memoli said. When the immunity weakened, the virus was given an opportunity to evolve.

Some other experts, including virologist Geert Vanden Bossche, have offered similar views. Others in the scientific community, such as U.S. Centers for Disease Control and Prevention scientists, say vaccination prevents virus evolution, though the agency has acknowledged it doesn’t have records supporting its position.

Other Messages

Dr. Memoli sent the email to Dr. Fauci and two other top NIAID officials, Drs. Hugh Auchincloss and Clifford Lane. The message was first reported by the Wall Street Journal, though the publication did not publish the message. The Epoch Times obtained the email and 199 other pages of Dr. Memoli’s emails through a Freedom of Information Act request. There were no indications that Dr. Fauci ever responded to Dr. Memoli.

Later in 2021, the NIAID’s parent agency, the U.S. National Institutes of Health (NIH), and all other federal government agencies began requiring COVID-19 vaccination, under direction from President Joe Biden.

In other messages, Dr. Memoli said the mandates were unethical and that he was hopeful legal cases brought against the mandates would ultimately let people “make their own healthcare decisions.”

“I am certainly doing everything in my power to influence that,” he wrote on Nov. 2, 2021, to an unknown recipient. Dr. Memoli also disclosed that both he and his wife had applied for exemptions from the mandates imposed by the NIH and his wife’s employer. While her request had been granted, his had not as of yet, Dr. Memoli said. It’s not clear if it ever was.

According to Dr. Memoli, officials had not gone over the bioethics of the mandates. He wrote to the NIH’s Department of Bioethics, pointing out that the protection from the vaccines waned over time, that the shots can cause serious health issues such as myocarditis, or heart inflammation, and that vaccinated people were just as likely to spread COVID-19 as unvaccinated people.

He cited multiple studies in his emails, including one that found a resurgence of COVID-19 cases in a California health care system despite a high rate of vaccination and another that showed transmission rates were similar among the vaccinated and unvaccinated.

Dr. Memoli said he was “particularly interested in the bioethics of a mandate when the vaccine doesn’t have the ability to stop spread of the disease, which is the purpose of the mandate.”

The message led to Dr. Memoli speaking during an NIH event in December 2021, several weeks after he went public with his concerns about mandating vaccines.

“Vaccine mandates should be rare and considered only with a strong justification,” Dr. Memoli said in the debate. He suggested that the justification was not there for COVID-19 vaccines, given their fleeting effectiveness.

Julie Ledgerwood, another NIAID official who also spoke at the event, said that the vaccines were highly effective and that the side effects that had been detected were not significant. She did acknowledge that vaccinated people needed boosters after a period of time.

The NIH, and many other government agencies, removed their mandates in 2023 with the end of the COVID-19 public health emergency.

A request for comment from Dr. Fauci was not returned. Dr. Memoli told The Epoch Times in an email he was “happy to answer any questions you have” but that he needed clearance from the NIAID’s media office. That office then refused to give clearance.

Dr. Jay Bhattacharya, a professor of health policy at Stanford University, said that Dr. Memoli showed bravery when he warned Dr. Fauci against mandates.

“Those mandates have done more to demolish public trust in public health than any single action by public health officials in my professional career, including diminishing public trust in all vaccines.” Dr. Bhattacharya, a frequent critic of the U.S. response to COVID-19, told The Epoch Times via email. “It was risky for Dr. Memoli to speak publicly since he works at the NIH, and the culture of the NIH punishes those who cross powerful scientific bureaucrats like Dr. Fauci or his former boss, Dr. Francis Collins.”

Tyler Durden Mon, 03/11/2024 - 17:40

Read More

Continue Reading

Government

Trump “Clearly Hasn’t Learned From His COVID-Era Mistakes”, RFK Jr. Says

Trump "Clearly Hasn’t Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President…

Published

on

Trump "Clearly Hasn't Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President Joe Biden claimed that COVID vaccines are now helping cancer patients during his State of the Union address on March 7, but it was a response on Truth Social from former President Donald Trump that drew the ire of independent presidential candidate Robert F. Kennedy Jr.

Robert F. Kennedy Jr. holds a voter rally in Grand Rapids, Mich., on Feb. 10, 2024. (Mitch Ranger for The Epoch Times)

During the address, President Biden said: “The pandemic no longer controls our lives. The vaccines that saved us from COVID are now being used to help beat cancer, turning setback into comeback. That’s what America does.”

President Trump wrote: “The Pandemic no longer controls our lives. The VACCINES that saved us from COVID are now being used to help beat cancer—turning setback into comeback. YOU’RE WELCOME JOE. NINE-MONTH APPROVAL TIME VS. 12 YEARS THAT IT WOULD HAVE TAKEN YOU.”

An outspoken critic of President Trump’s COVID response, and the Operation Warp Speed program that escalated the availability of COVID vaccines, Mr. Kennedy said on X, formerly known as Twitter, that “Donald Trump clearly hasn’t learned from his COVID-era mistakes.”

“He fails to recognize how ineffective his warp speed vaccine is as the ninth shot is being recommended to seniors. Even more troubling is the documented harm being caused by the shot to so many innocent children and adults who are suffering myocarditis, pericarditis, and brain inflammation,” Mr. Kennedy remarked.

“This has been confirmed by a CDC-funded study of 99 million people. Instead of bragging about its speedy approval, we should be honestly and transparently debating the abundant evidence that this vaccine may have caused more harm than good.

“I look forward to debating both Trump and Biden on Sept. 16 in San Marcos, Texas.”

Mr. Kennedy announced in April 2023 that he would challenge President Biden for the 2024 Democratic Party presidential nomination before declaring his run as an independent last October, claiming that the Democrat National Committee was “rigging the primary.”

Since the early stages of his campaign, Mr. Kennedy has generated more support than pundits expected from conservatives, moderates, and independents resulting in speculation that he could take votes away from President Trump.

Many Republicans continue to seek a reckoning over the government-imposed pandemic lockdowns and vaccine mandates.

President Trump’s defense of Operation Warp Speed, the program he rolled out in May 2020 to spur the development and distribution of COVID-19 vaccines amid the pandemic, remains a sticking point for some of his supporters.

Vice President Mike Pence (L) and President Donald Trump deliver an update on Operation Warp Speed in the Rose Garden of the White House in Washington on Nov. 13, 2020. (Mandel Ngan/AFP via Getty Images)

Operation Warp Speed featured a partnership between the government, the military, and the private sector, with the government paying for millions of vaccine doses to be produced.

President Trump released a statement in March 2021 saying: “I hope everyone remembers when they’re getting the COVID-19 Vaccine, that if I wasn’t President, you wouldn’t be getting that beautiful ‘shot’ for 5 years, at best, and probably wouldn’t be getting it at all. I hope everyone remembers!”

President Trump said about the COVID-19 vaccine in an interview on Fox News in March 2021: “It works incredibly well. Ninety-five percent, maybe even more than that. I would recommend it, and I would recommend it to a lot of people that don’t want to get it and a lot of those people voted for me, frankly.

“But again, we have our freedoms and we have to live by that and I agree with that also. But it’s a great vaccine, it’s a safe vaccine, and it’s something that works.”

On many occasions, President Trump has said that he is not in favor of vaccine mandates.

An environmental attorney, Mr. Kennedy founded Children’s Health Defense, a nonprofit that aims to end childhood health epidemics by promoting vaccine safeguards, among other initiatives.

Last year, Mr. Kennedy told podcaster Joe Rogan that ivermectin was suppressed by the FDA so that the COVID-19 vaccines could be granted emergency use authorization.

He has criticized Big Pharma, vaccine safety, and government mandates for years.

Since launching his presidential campaign, Mr. Kennedy has made his stances on the COVID-19 vaccines, and vaccines in general, a frequent talking point.

“I would argue that the science is very clear right now that they [vaccines] caused a lot more problems than they averted,” Mr. Kennedy said on Piers Morgan Uncensored last April.

“And if you look at the countries that did not vaccinate, they had the lowest death rates, they had the lowest COVID and infection rates.”

Additional data show a “direct correlation” between excess deaths and high vaccination rates in developed countries, he said.

President Trump and Mr. Kennedy have similar views on topics like protecting the U.S.-Mexico border and ending the Russia-Ukraine war.

COVID-19 is the topic where Mr. Kennedy and President Trump seem to differ the most.

Former President Donald Trump intended to “drain the swamp” when he took office in 2017, but he was “intimidated by bureaucrats” at federal agencies and did not accomplish that objective, Mr. Kennedy said on Feb. 5.

Speaking at a voter rally in Tucson, where he collected signatures to get on the Arizona ballot, the independent presidential candidate said President Trump was “earnest” when he vowed to “drain the swamp,” but it was “business as usual” during his term.

John Bolton, who President Trump appointed as a national security adviser, is “the template for a swamp creature,” Mr. Kennedy said.

Scott Gottlieb, who President Trump named to run the FDA, “was Pfizer’s business partner” and eventually returned to Pfizer, Mr. Kennedy said.

Mr. Kennedy said that President Trump had more lobbyists running federal agencies than any president in U.S. history.

“You can’t reform them when you’ve got the swamp creatures running them, and I’m not going to do that. I’m going to do something different,” Mr. Kennedy said.

During the COVID-19 pandemic, President Trump “did not ask the questions that he should have,” he believes.

President Trump “knew that lockdowns were wrong” and then “agreed to lockdowns,” Mr. Kennedy said.

He also “knew that hydroxychloroquine worked, he said it,” Mr. Kennedy explained, adding that he was eventually “rolled over” by Dr. Anthony Fauci and his advisers.

President Donald Trump greets the crowd before he leaves at the Operation Warp Speed Vaccine Summit in Washington on Dec. 8, 2020. (Tasos Katopodis/Getty Images)

MaryJo Perry, a longtime advocate for vaccine choice and a Trump supporter, thinks votes will be at a premium come Election Day, particularly because the independent and third-party field is becoming more competitive.

Ms. Perry, president of Mississippi Parents for Vaccine Rights, believes advocates for medical freedom could determine who is ultimately president.

She believes that Mr. Kennedy is “pulling votes from Trump” because of the former president’s stance on the vaccines.

“People care about medical freedom. It’s an important issue here in Mississippi, and across the country,” Ms. Perry told The Epoch Times.

“Trump should admit he was wrong about Operation Warp Speed and that COVID vaccines have been dangerous. That would make a difference among people he has offended.”

President Trump won’t lose enough votes to Mr. Kennedy about Operation Warp Speed and COVID vaccines to have a significant impact on the election, Ohio Republican strategist Wes Farno told The Epoch Times.

President Trump won in Ohio by eight percentage points in both 2016 and 2020. The Ohio Republican Party endorsed President Trump for the nomination in 2024.

“The positives of a Trump presidency far outweigh the negatives,” Mr. Farno said. “People are more concerned about their wallet and the economy.

“They are asking themselves if they were better off during President Trump’s term compared to since President Biden took office. The answer to that question is obvious because many Americans are struggling to afford groceries, gas, mortgages, and rent payments.

“America needs President Trump.”

Multiple national polls back Mr. Farno’s view.

As of March 6, the RealClearPolitics average of polls indicates that President Trump has 41.8 percent support in a five-way race that includes President Biden (38.4 percent), Mr. Kennedy (12.7 percent), independent Cornel West (2.6 percent), and Green Party nominee Jill Stein (1.7 percent).

A Pew Research Center study conducted among 10,133 U.S. adults from Feb. 7 to Feb. 11 showed that Democrats and Democrat-leaning independents (42 percent) are more likely than Republicans and GOP-leaning independents (15 percent) to say they have received an updated COVID vaccine.

The poll also reported that just 28 percent of adults say they have received the updated COVID inoculation.

The peer-reviewed multinational study of more than 99 million vaccinated people that Mr. Kennedy referenced in his X post on March 7 was published in the Vaccine journal on Feb. 12.

It aimed to evaluate the risk of 13 adverse events of special interest (AESI) following COVID-19 vaccination. The AESIs spanned three categories—neurological, hematologic (blood), and cardiovascular.

The study reviewed data collected from more than 99 million vaccinated people from eight nations—Argentina, Australia, Canada, Denmark, Finland, France, New Zealand, and Scotland—looking at risks up to 42 days after getting the shots.

Three vaccines—Pfizer and Moderna’s mRNA vaccines as well as AstraZeneca’s viral vector jab—were examined in the study.

Researchers found higher-than-expected cases that they deemed met the threshold to be potential safety signals for multiple AESIs, including for Guillain-Barre syndrome (GBS), cerebral venous sinus thrombosis (CVST), myocarditis, and pericarditis.

A safety signal refers to information that could suggest a potential risk or harm that may be associated with a medical product.

The study identified higher incidences of neurological, cardiovascular, and blood disorder complications than what the researchers expected.

President Trump’s role in Operation Warp Speed, and his continued praise of the COVID vaccine, remains a concern for some voters, including those who still support him.

Krista Cobb is a 40-year-old mother in western Ohio. She voted for President Trump in 2020 and said she would cast her vote for him this November, but she was stunned when she saw his response to President Biden about the COVID-19 vaccine during the State of the Union address.

I love President Trump and support his policies, but at this point, he has to know they [advisers and health officials] lied about the shot,” Ms. Cobb told The Epoch Times.

“If he continues to promote it, especially after all of the hearings they’ve had about it in Congress, the side effects, and cover-ups on Capitol Hill, at what point does he become the same as the people who have lied?” Ms. Cobb added.

“I think he should distance himself from talk about Operation Warp Speed and even admit that he was wrong—that the vaccines have not had the impact he was told they would have. If he did that, people would respect him even more.”

Tyler Durden Mon, 03/11/2024 - 17:00

Read More

Continue Reading

Trending